L&C Bio Co. Ltd (KQ:290650) — Market Cap & Net Worth
Market Cap & Net Worth: L&C Bio Co. Ltd (290650)
L&C Bio Co. Ltd (KQ:290650) has a market capitalization of $1.30 Billion (₩1.93 Trillion) as of June 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #7948 globally and #216 in its home market, demonstrating a -6.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying L&C Bio Co. Ltd's stock price ₩78200.00 by its total outstanding shares 24618850 (24.62 Million). Review L&C Bio Co. Ltd (290650) financial obligations to assess the company's total debt and financial obligations.
L&C Bio Co. Ltd Market Cap History: 2018 to 2026
L&C Bio Co. Ltd's market capitalization history from 2018 to 2026. Data shows growth from $107.91 Million to $1.30 Billion (33.02% CAGR).
Index Memberships
L&C Bio Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$273.60 Billion | 0.48% | #43 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$273.60 Billion | 0.48% | #43 of 1384 |
Weight: L&C Bio Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
L&C Bio Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how L&C Bio Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
L&C Bio Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
L&C Bio Co. Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $107.91 Million | $21.24 Billion | $5.21 Billion | 0.01x | 0.02x |
| 2019 | $141.16 Million | $29.15 Billion | $7.25 Billion | 0.00x | 0.02x |
| 2020 | $571.59 Million | $32.97 Billion | $10.81 Billion | 0.02x | 0.05x |
| 2021 | $607.24 Million | $45.68 Billion | $13.81 Billion | 0.01x | 0.04x |
| 2022 | $384.07 Million | $52.57 Billion | $4.54 Billion | 0.01x | 0.08x |
| 2023 | $483.83 Million | $65.93 Billion | $48.36 Billion | 0.01x | 0.01x |
| 2024 | $402.08 Million | $72.09 Billion | $141.06 Billion | 0.01x | 0.00x |
Competitor Companies of 290650 by Market Capitalization
Companies near L&C Bio Co. Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to L&C Bio Co. Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $157.58 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $118.86 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #244 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $157.58 Billion | $90.62 |
| #205 | Stryker Corporation | NYSE:SYK | $118.86 Billion | $310.58 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #244 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $81.32 |
L&C Bio Co. Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, L&C Bio Co. Ltd's market cap moved from $107.91 Million to $ 1.30 Billion, with a yearly change of 33.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.30 Billion | +27.99% |
| 2025 | ₩1.02 Billion | +153.53% |
| 2024 | ₩402.08 Million | -16.90% |
| 2023 | ₩483.83 Million | +25.97% |
| 2022 | ₩384.07 Million | -36.75% |
| 2021 | ₩607.24 Million | +6.24% |
| 2020 | ₩571.59 Million | +304.91% |
| 2019 | ₩141.16 Million | +30.81% |
| 2018 | ₩107.91 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of L&C Bio Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.